Fineline Cube

Follow:
14422 Articles
Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration
CompanyDeals

Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment
CompanyDeals

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention
CompanyDrug

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults
CompanyDrug

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs
Policy / Regulatory

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors
CompanyDrug

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide
CompanyDrug

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule
CompanyDeals

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy
CompanyDeals

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma
CompanyDeals

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
CompanyDrug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer
CompanyDrug

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer